Blood marker can predict heart disease risk in type-2 diabetes patients

Measuring a blood marker, copeptin, can successfully predict the risk of heart attacks in people with type-2 diabetes. This research presented at the European Congress of Endocrinology, suggests the copeptin molecule as a potential target to predict and prevent heart disease in diabetic patients.

Type-2 diabetes affects about 60 million people in Europe and is associated with a number of debilitating conditions, including blindness and kidney failure.Type-2 diabetes can also increase the risk of coronary artery disease and stroke, which can lead to premature death.

Copeptin is a fragment of the hormone vasopressin, also known as antidiuretic hormone, which is involved in many physiological processes related to heart disease including water retention in the kidneys, blood vessel contraction, sugar metabolism in the liver and hormone secretion from the pancreas.

In this study, carried out by researchers at Linköping University in Sweden, levels of copeptin were measured in the blood of 681 type-2 diabetes patients. During a seven year follow-up of this group, deaths and hospitalisation due to heart attack or stroke were recorded.

The researchers found that over the seven-year-period, there was an association between levels of copeptin at the start of the study and the likelihood of later heart disease events. Once the data were adjusted for other influencing factors, the results indicated that patients were more than twice as likely to experience heart attack or stroke for every 1 pmol/L increase in blood copeptin levels.

Dr Simona Ioana Chisalita who led the study said, “these results suggest that in type-2 diabetes patients, levels of copeptin can predict cardiovascular disease independently of well-established risk factors.”

The results, however, should be interpreted cautiously - the group had relatively low rates of mortality and morbidity during the study period. This is likely due to the short follow-up period and to the fact that patients had well-controlled diabetes. The studied group was also predominantly Caucasian, so the results cannot be extrapolated to other ethnic groups.

“Earlier identification of diabetes patients at high risk of developing severe complications will help develop new therapeutic targets for the prevention of secondary diseases and death”, states study leader Dr Chisalita. “The next step is to develop a set of new markers that can predict cardiovascular complications in diabetes patients earlier and more accurately, in order to help physicians pin down the specific risks for individual patients and apply appropriate preventative measures.”

 

Abstract OC6.4

Copeptin and its association to cardiovascular dysfunction in type 2 diabetes

Simona Ioana Chisalita1, Lee Ti Chong2, Fredrik Nyström1, Carl Johan Östgren3, Toste Länne4

1Department of Endocrinology and Department of Medicine and Health Sciences, Linköping University, Linköping, Sweden, Linköping, Sweden, 2Department of Emergency and Department of Medicine and Health Sciences, Linköping University, Linköping, Sweden, Linköping, Sweden, 3Department of Medical and Health Sciences (IMH) / Division of Community, Linköping, Sweden, 4Department of Thoracic and Vascular Surgery, and Department of Medicine and Health Sciences, Linköping University, Linköping, Sweden, Linköping, Sweden

Background: We aim to test whether plasma copeptin (copeptin), the C-terminal fragment of vasopressin, has predictive value of cardiovascular events in patients with type 2 diabetes without previous cardiovascular disease who were treated in primary care.

Methods: We measured copeptin in 697 patients who participated in the epidemiological study CARDIPP (Cardiovascular Risk Factors in Patients with Diabetes—a Prospective Study in Primary Care; ClinicalTrials.gov identifier NCT01049737) and who did not have previously known myocardial infarction or stroke. The outcome variable was a composite endpoint consisting of cardiovascular mortality, hospitalization for myocardial infarction and hospitalization for stroke.

Results: During a median follow-up time of almost 7 years, the unadjusted HR per each increment of Copeptin by 1 pmol/L was 3.5 (95% CI 1.7–7.1, p < 0.001) for the primary endpoint. Following adjustments for age, sex, HbA1c, arterial stiffness (PWW) as well as atherosclerosis plaque the adjusted hazard ratio was 2.4 (95% CI 1.1–5.2, P = 0.03).

Conclusions: In primary preventive patients with type 2 diabetes treated in primary care, copeptin predicted a composite outcome of incident cardiovascular events independently of age, sex, HbA1c, arterial stiffness as well as atherosclerosis plaque.

Notes for Editors

For further information about the study please contact:

Ioana Simona Chisalita, MD PhD

University Hospital Linköping

Universitetssjukhuset Linköping

Sweden

Email: ioana.simona.chisalita@liu.se

Phone: +460101030000

The study Copeptin and its association to cardiovascular dysfunction in type 2 diabetes is an oral presentation at the European Congress of Endocrinology at the Centro de Congressos de Lisboa, in Lisbon, Portugal.

For other press enquiries please contact the ECE 2017 press office:

Lynsey Forsyth

Communications Manager

European Society of Endocrinology

Tel: (+44) (0)1454 642252

Mob: (+44) (0)7876824027

Email: lynsey.forsyth@bioscientifica.com

The European Congress of Endocrinology is held at the Centro de Congressos de Lisboa, 20-23 May 2017. View the scientific programme for further information.

At the European Society of Endocrinology (ESE), we’re working together to develop and share the best knowledge in endocrine science and medicine.

ESE represents a community of over 20,000 European endocrinologists, enabling us to inform policy makers on health decisions at the highest level through engagement in advocacy efforts across Europe. It is by uniting and representing every part of the endocrine community that we are placed in the best possible position to improve life for the patient.